Higher expression of PD-L1, LAG3, TGFB1, TNFSF13, CD4, CD40, CD80, and CD276 was found in the high-risk group, which may enhance AML development and progression, leading to poor prognostic outcomes. This evidence concerns the gene CD4 and acute myeloid leukemia.